\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe Horizon Europe funded ERA4Health partnership has recently launched a new call for projects focusing on 'Understanding the interactions between cardiovascular disorders and comorbidities and/or their therapeutic treatments' - InterHeart 2025.
Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on how to apply is availabe here.
Background: The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) for Health and Well-being. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Agro-Food, Environment
The 2nd EO 4 Soil Symposium is organised by the European Space Agency (ESA) and focusses on three thematic areas: policy and user uptake scientific and technical progress applications and use cases Topics include soil monitoring methods, soil organic carbon mapping, uncertainty assessment, data harmonisation, soil carbon certific... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
